Lululemon Cuts Earnings Forecast, Joins DocuSign, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were up this morning, while several companies saw significant pre-market declines after releasing earnings or guidance; Lululemon shares fell over 20% after lowering full-year EPS guidance to $14.58-$14.78, below the $14.88 analyst estimate, despite beating Q1 revenue estimates. Other notable pre-market movers included Vera Therapeutics down 34.7%, DocuSign down 19.2% despite better-than-expected Q1 results and increased share repurchase program, and Samsara Inc. down 13.5% following Q1 results.

Analysis

U.S. stock market futures indicated a positive open, with Dow futures gaining approximately 100 points, suggesting broader market optimism. This positive sentiment, however, contrasted sharply with significant pre-market declines in several individual stocks, primarily driven by earnings announcements and revised corporate guidance. Lululemon Athletica (LULU) experienced a substantial 20.9% pre-market drop to $261.60 after reducing its FY25 GAAP EPS guidance to $14.58-$14.78, below its prior range of $14.95-$15.15 and analyst consensus of $14.88, despite reporting a marginal beat on Q1 revenue at $2.37 billion. This negative revision overshadowed the revenue performance, signaling concerns about future profitability. Similarly, Braze (BRZE) fell 8.6% after cutting its FY26 adjusted EPS guidance, Petco (WOOF) declined 10.2% due to worse-than-expected Q1 sales results, and Samsara (IOT) also fell 13.5% following its Q1 report.

A particularly divergent situation was observed with DocuSign (DOCU), which fell 19.2% in pre-market trading despite posting better-than-expected Q1 results, announcing a $1 billion increase to its share repurchase program, and raising its FY26 revenue outlook to $3.15-$3.16 billion (versus the $3.14 billion estimate). This significant negative market reaction to objectively positive news, especially when its per-ticker sentiment was a slightly positive 0.3, warrants closer scrutiny for underlying investor concerns that may not be immediately apparent from the headline results. Other notable movers included Vera Therapeutics (VERA), down 34.7%, and Liminatus Pharma (LIMN), which dipped 15.8%, likely due to profit-taking after Thursday's 94% surge on achieving Nasdaq compliance. These individual stock movements underscore a market acutely sensitive to forward-looking statements and profitability metrics, even when broader market indices suggest optimism.

Key Decisions for Investors

• Re-evaluate Lululemon's (LULU) long-term profit forecasts and competitive positioning given the significant earnings guidance cut, which overshadowed its Q1 revenue beat and signals potential margin pressure.
• Investigate underlying factors contributing to DocuSign's (DOCU) sharp price decline, such as valuation concerns or perceived sustainability of growth, despite its positive Q1 results, increased buyback, and raised guidance.
• Recognize the heightened market sensitivity to forward guidance; prioritize companies with strong, transparent outlooks and exercise caution with those showing deteriorating earnings forecasts, as evidenced by severe reactions to LULU and BRZE.
• Monitor stocks like Liminatus Pharma (LIMN) for continued volatility and potential further correction following significant event-driven price surges, as profit-taking often follows such sharp upward movements.